1.82
+0.07(+4.00%)
Currency In USD
| Previous Close | 1.75 |
| Open | 1.79 |
| Day High | 1.84 |
| Day Low | 1.76 |
| 52-Week High | 12.54 |
| 52-Week Low | 1.53 |
| Volume | 36,098 |
| Average Volume | 70,690 |
| Market Cap | 8.43M |
| PE | -0.35 |
| EPS | -5.26 |
| Moving Average 50 Days | 1.98 |
| Moving Average 200 Days | 3.46 |
| Change | 0.07 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $182 as of December 05, 2025 at a share price of $1.82. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 3 years ago, it would be worth $745.9 as of December 05, 2025 at a share price of $1.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
GlobeNewswire Inc.
Oct 29, 2025 12:00 PM GMT
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State Universit
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for safer deep B
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
GlobeNewswire Inc.
Jun 09, 2025 11:00 AM GMT
Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trialNEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8b